In our study, we identified this abnormality in a patient with AML with myelodysplasia-related changes (AML-MRC), where the presence of KMT2A-PTD, together with high-risk mutations, may have contributed to the leukemic transformation from an underlying MDS. The gene discussed is KMT2A; the disease is myelodysplastic syndrome.